Radius Health Receives FDA Fast Track Designation for Elacestrant
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for elacestrant, an investigational oral selective estrogen receptor down-regulator/degrader (SERD) as a treatment of women with ER+ and HER2- advanced or metastatic breast cancer. Fast Track designation is a process designed to facilitate the development and expedite the review of new therapies and check out our website to treat serious conditions and fill unmet medical needs.
Plastic Surgery Phoenix | Elite Plastic Surgery | Board Certified Plastic Surgeons
Elite Plastic Surgery serves the Phoenix, Scottsdale & Surrounding AZ areas to provide a broad range of SURGICAL and NON-SURGICAL cosmetic procedures for women and men. We also provide the most advanced breast reconstruction surgery available in Arizona. Cosmetic. Reconstructive. Board Certified Plastic Surgeons
About Elacestrant (RAD1901)
Elacestrant is a selective estrogen receptor down-regulator/degrader (SERD), which at high doses is being evaluated for potential use as an oral non-steroidal treatment for hormone-driven or hormone-resistant breast cancer. Elacestrant is currently being investigated for potential use in postmenopausal women with estrogen receptor positive breast cancer, the most common form of the disease. Studies completed to date indicate that the compound has the potential for use as a single agent or in combination with other therapies for the treatment of breast cancer.
Radius Health Receives FDA Fast Track Designation for Elacestrant (RAD1901)
- Radius plans to initiate Phase 2 clinical study of elacestrant as a third-line therapy for women with ER+ and HER2- breast cancer early in 2018 - - Phase 2 Study is a potentially pivotal trial for accelerated approval - WALTHAM, Mass., Oct. 18, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. (
Copyright © 2018 CancerConnect. All Rights Reserved.